We are live on ! Find out more
PS

Peter Svennilson Portfolio holdings

AUM $1.23B
1-Year Est. Return 301.34%
This Fund
S&P 500
This Quarter Est. Return
-6.34%
1 Year Est. Return
+301.34%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$162M
Cap. Flow
+$191M
Cap. Flow %
54.54%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$230M

Top Sells

Rank Stock Value
1
IMDZ
Immune Design Corp.
IMDZ
+$38.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
1
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$230M 65.66%
+15,694,091
New +$230M
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$57.4M 16.42%
4,677,939
– –
GRTS
3
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$34.6M 9.88%
3,102,934
– –
RCUS icon
4
Arcus Biosciences
RCUS
$3.55B
$28.1M 8.04%
3,540,850
– –
IMDZ
5
DELISTED
Immune Design Corp.
IMDZ
– –
-6,642,942
Closed -$38.9M

Similar funds

CT
CGM Trust Boston, Massachusetts $957M AUM
CAW
Cornerstone Advisors (Washington) Bellevue, Washington $936M AUM 8.77% 1-Year Est. Return
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
SFSG
Stearns Financial Services Group Greensboro, North Carolina $639M AUM 11.66% 1-Year Est. Return
KFA
Kays Financial Advisory Atlanta, Georgia $624M AUM 9.93% 1-Year Est. Return
11A
10-15 Associates Goshen, New York $516M AUM 7.62% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
IA
Independence Advisors Wayne, Pennsylvania $466M AUM 11.32% 1-Year Est. Return

Peter Svennilson's Q2 2019 Portfolio in Review

As of Q2 2019, Peter Svennilson held 5 positions worth $350M, up 86% from $188M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Peter Svennilson deployed $191M of net new capital in Q2 2019, opening 1 new position. Its largest new stake was NGM Biopharmaceuticals, Inc. Common Stock: 15,694,091 shares worth $230M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 79% a quarter earlier.

On the sell side, the most notable exit was Immune Design Corp., an estimated $38.9M sold.

  • Peter Svennilson's largest Q2 2019 buy was NGM Biopharmaceuticals, Inc. Common Stock: 15,694,091 shares worth $230M.
  • Peter Svennilson fully exited Immune Design Corp. in Q2 2019, selling an estimated $38.9M.
  • Peter Svennilson's ten largest holdings make up 100% of its $350M portfolio in Q2 2019.
  • Peter Svennilson opened 1 new position and closed 1 in Q2 2019.
  • Peter Svennilson's portfolio value rose 86% quarter-over-quarter to $350M.

Based on Peter Svennilson's 13F filing for Q2 2019, filed 14 Aug 2019.